Proteomics

Dataset Information

0

Interactions of Histone Deacetylase 6 with DNA damage repair fac-tors strengthens its utility as a combination drug target in high-grade serous ovarian cancer


ABSTRACT: High-grade serous ovarian cancer (HGSOC) is the deadliest gynecologic malignancy in women.The lack of effective second line therapeutics remains a substantial challenge for BRCA-1/2 wildtype HGSOC patients, and contributes to poor survival rates due to drug resistance. There is a striking need to elucidate and implement new and alternative treatment options for patients with HGSOC. Histone Deacetylases (HDACs) are promising targets in HGSOC treat-ment, however, the mechanism and efficacy of HDAC inhibitors is understudied in HGSOC. In order to consider HDACs as a treatment target, we need to better understand how they are functioning within HGSOC. This includes elucidating HDAC6 protein-protein interactions. In this study, we carried out substrate trapping to elucidate HDAC6-specific interactors in the context of BRCA-1/2 wildtype HGSOC

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Epithelial Cell

DISEASE(S): Malignant Neoplasm Of Ovary

SUBMITTER: Jolene Duda  

LAB HEAD: Stefani N Thomas

PROVIDER: PXD044705 | Pride | 2023-12-28

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
20230120_Vehicle_NT_R1_F1.raw Raw
20230120_Vehicle_NT_R1_F2.raw Raw
20230120_Vehicle_NT_R1_F3.raw Raw
20230123_CD12_NT_R1_F1.raw Raw
20230123_CD12_NT_R1_F2.raw Raw
Items per page:
1 - 5 of 227
altmetric image

Publications

Interactions of Histone Deacetylase 6 with DNA Damage Repair Factors Strengthen its Utility as a Combination Drug Target in High-Grade Serous Ovarian Cancer.

Duda Jolene M JM   Thomas Stefani N SN  

ACS pharmacology & translational science 20231116 12


High-grade serous ovarian cancer (HGSOC) is the deadliest gynecologic malignancy in women. The low survival rate is largely due to drug resistance. Approximately 80% of patients who initially respond to treatment relapse and become drug-resistant. The lack of effective second-line therapeutics remains a substantial challenge for BRCA-1/2 wild-type HGSOC patients. Histone Deacetylases (HDACs) are promising targets in HGSOC treatment; however, the mechanism and efficacy of HDAC inhibitors are unde  ...[more]

Similar Datasets

2017-01-30 | E-MTAB-4667 | biostudies-arrayexpress
2023-10-24 | PXD020024 | Pride
2024-01-10 | GSE252610 | GEO
2013-11-20 | E-GEOD-42208 | biostudies-arrayexpress
2023-10-17 | PXD038816 | Pride
2011-05-01 | E-GEOD-27896 | biostudies-arrayexpress
2021-03-15 | PXD023852 | Pride
2016-06-01 | E-GEOD-70016 | biostudies-arrayexpress
2015-09-29 | GSE69428 | GEO
2011-12-07 | E-GEOD-34229 | biostudies-arrayexpress